Do Analysts See Any Upside for bluebird bio Stock?

In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million compared to its net interest expense of $1.15 million in the previous year’s period. The company’s net income fell YoY (year-over-year) to -$145.48 million from -$78.8 million, translating to a net income per share of -$2.73. Of the 23 analysts covering bluebird bio stock, 16 have given it “buy” or higher ratings, and seven have given it “holds.” Analysts’ mean rating for bluebird stock is 1.96, and their target price is $184.94, implying a potential 79.9% upside for the stock based on its December 18 price of $102.79.